Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of turoctocog alfa pegol prophylaxis and bleeding treatment in previously treated patients with severe hemophilia A
MOH_2018-03-12_002054Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of octocog alfa in hemophilia A (3 arms), sponsored by Novo Nordisk. Started Mar 2018; status: completed.
02
Drugs
octocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on MOH_2018-03-12_002054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-03-12_002054.